GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » PS Ratio

China Regenerative Medicine International (HKSE:08158) PS Ratio : 1.07 (As of Mar. 04, 2025)


View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, China Regenerative Medicine International's share price is HK$0.27. China Regenerative Medicine International's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.25. Hence, China Regenerative Medicine International's PS Ratio for today is 1.07.

The historical rank and industry rank for China Regenerative Medicine International's PS Ratio or its related term are showing as below:

HKSE:08158' s PS Ratio Range Over the Past 10 Years
Min: 0.64   Med: 7.6   Max: 3555.56
Current: 1.07

During the past 13 years, China Regenerative Medicine International's highest PS Ratio was 3555.56. The lowest was 0.64. And the median was 7.60.

HKSE:08158's PS Ratio is ranked better than
92.02% of 1003 companies
in the Biotechnology industry
Industry Median: 8.69 vs HKSE:08158: 1.07

China Regenerative Medicine International's Revenue per Sharefor the three months ended in Jun. 2024 was HK$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.25.

Warning Sign:

China Regenerative Medicine International Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of China Regenerative Medicine International was -58.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was -40.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -19.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 30.20% per year.

During the past 13 years, China Regenerative Medicine International's highest 3-Year average Revenue per Share Growth Rate was 640.50% per year. The lowest was -95.10% per year. And the median was -13.90% per year.

Back to Basics: PS Ratio


China Regenerative Medicine International PS Ratio Historical Data

The historical data trend for China Regenerative Medicine International's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Regenerative Medicine International PS Ratio Chart

China Regenerative Medicine International Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.45 5.03 2.83 7.60 2.26

China Regenerative Medicine International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.68 3.78 - 2.26 -

Competitive Comparison of China Regenerative Medicine International's PS Ratio

For the Biotechnology subindustry, China Regenerative Medicine International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Regenerative Medicine International's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's PS Ratio distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's PS Ratio falls into.



China Regenerative Medicine International PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

China Regenerative Medicine International's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.27/0.252
=1.07

China Regenerative Medicine International's Share Price of today is HK$0.27.
China Regenerative Medicine International's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.25.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


China Regenerative Medicine International  (HKSE:08158) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


China Regenerative Medicine International PS Ratio Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


China Regenerative Medicine International Business Description

Traded in Other Exchanges
N/A
Address
132 Nathan Road, Suite 2310–18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.
Executives
Central Huijin Investment Ltd. 2201 Interest of corporation controlled by you
Wang Chuang 2101 Beneficial owner
Arab Osman Mohammed 2501 Other
Wong Kwok Keung 2501 Other
Lei Changjuan 2101 Beneficial owner
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Kong Yudong 2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Li Ren 2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited) 2201 Interest of corporation controlled by you
All Favour Holdings Limited 2101 Beneficial owner
Deng Shufen 2202 Interest of your spouse
Dai Yumin 2201 Interest of corporation controlled by you
Wang Xiaogang 2101 Beneficial owner
China Orient Asset Management Co., Ltd. 2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines